Unknown

Dataset Information

0

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.


ABSTRACT: The UGT1A1*28 polymorphism was suggested to be significantly connected with irinotecan-induced toxicity and response to chemotherapy. However, the results of previous studies are controversial. Hence we carried out a meta-analysis to investigate the effect of UGT1A1*28 polymorphism on severe diarrhea, neutropenia, and response of patients who had undergone irinotecan-based chemotherapy. The PubMed, Web of Science, Wanfang, and CNKI databases were searched for clinical trials assessing the association of UGT1A1*28 polymorphism with severe diarrhea, neutropenia, and response to irinotecan-based chemotherapy. The combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the relationship under a fixed- or random-effects model. Fifty-eight studies including 6087 patients with cancer were included. Our results showed that patients carrying the TA6/7 and TA7/7 genotypes had a greater prevalence of diarrhea and neutropenia than those with the TA6/6 genotype (TA6/7+TA7/7 vs. TA6/6: diarrhea, OR = 2.18, 95%CI = 1.68-2.83; neutropenia, OR = 2.15, 95%CI = 1.71-2.70), particularly patients with metastatic colorectal cancer. Stratified analysis showed that Asians with the TA6/7 and TA7/7 genotypes were more likely to have diarrhea and neutropenia, and Caucasians with the TA6/7 and TA7/7 genotypes were more likely to have neutropenia than other groups. However, patients with the TA6/7+TA7/7 genotypes showed a higher response than patients with TA6/6 genotype (OR = 1.20, 95%CI = 1.07-1.34), particularly Caucasians (OR = 1.23, 95%CI = 1.06-1.42) and patients with metastatic colorectal cancer (OR = 1.24, 95%CI = 1.05-1.48). Our data showed that the UGT1A1*28 polymorphism had a significant relationship with toxicity and response to irinotecan-based chemotherapy. This polymorphism may be useful as a monitoring index for cancer patients receiving irinotecan-based chemotherapy.

SUBMITTER: Liu XH 

PROVIDER: S-EPMC5370513 | biostudies-other | 2017

REPOSITORIES: biostudies-other

altmetric image

Publications

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.

Liu Xing-Han XH   Lu Jun J   Duan Wei W   Dai Zhi-Ming ZM   Wang Meng M   Lin Shuai S   Yang Peng-Tao PT   Tian Tian T   Liu Kang K   Zhu Yu-Yao YY   Zheng Yi Y   Sheng Qian-Wen QW   Dai Zhi-Jun ZJ  

Journal of Cancer 20170225 4


The UGT1A1*28 polymorphism was suggested to be significantly connected with irinotecan-induced toxicity and response to chemotherapy. However, the results of previous studies are controversial. Hence we carried out a meta-analysis to investigate the effect of UGT1A1*28 polymorphism on severe diarrhea, neutropenia, and response of patients who had undergone irinotecan-based chemotherapy. The PubMed, Web of Science, Wanfang, and CNKI databases were searched for clinical trials assessing the associ  ...[more]

Similar Datasets

| S-EPMC5488790 | biostudies-other
| S-EPMC3699040 | biostudies-literature
| S-EPMC9284221 | biostudies-literature
| S-EPMC7578622 | biostudies-literature
| S-EPMC2768885 | biostudies-literature
| S-EPMC3597733 | biostudies-literature
| S-EPMC5528002 | biostudies-literature
| S-EPMC8586680 | biostudies-literature
| S-EPMC9283744 | biostudies-literature
| S-EPMC2480976 | biostudies-literature